Repligen pancreatic imaging agent succeeds in Phase III study, shares rise
This article was originally published in Scrip
Executive Summary
A week after its shares took a 30% hit following the failure of its investigational biopolar depression drug to outperform a placebo in a midstage study, Repligen got a needed boost when top-line Phase III results showed that the firm's synthetic human secretin RG1068 improved the readability of magnetic resonance imaging (MRI) in identifying structural abnormalities of the pancreatic ducts in patients with acute or chronic pancreatitis (scripintelligence, 8 March 2011).
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.